Efficacy and safety of alemtuzumab in treatment-naive patients with relapsing-remitting MS: Four-year follow-up of the CARE-MS I study

The requested reference [dad7e44da6af212dea959801e6b64b5cc6980c2f] no longer exists in our database. It has been replaced by the current reference: [4262e9377fe36e531703a7bc975649e1c1359b9b]

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2015
This article has no abstract
Epistemonikos ID: d3b5c90a64a79566771bc0d5d2af7465ae8438f1
First added on: Apr 29, 2026